In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.

J M Reimund, S Dumont, C D Muller, J S Kenney, M Kedinger, R Baumann, P Poindron, B Duclos

Service d'Hépatogastroentérologie et d'Assistance Nutritive, CHRU Hautepierre, Strasbourg, France.

BACKGROUND: Inflammatory cytokines, including tumour necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 beta, have been implicated as primary mediators of intestinal inflammation in inflammatory bowel disease. AIM: To investigate the in vitro effects of oxpentifylline (pentoxifylline; PTX; a phosphodiesterase inhibitor) on inflammatory cytokine production (1) by peripheral mononuclear cells (PBMCs) and (2) by inflamed intestinal mucosa cultures from patients with Crohn's disease and patients with ulcerative colitis. METHODS: PBMCs and mucosal biopsy specimens were cultured for 24 hours in the absence or presence of PTX (up to 100 micrograms/ml), and the secretion of TNF-alpha, IL-1 beta, IL-6, and IL-8 determined by enzyme linked immunosorbent assays (ELISAs). RESULTS: PTX inhibited the release of TNF-alpha by PBMCs from patients with inflammatory bowel disease and the secretion of TNF-alpha and IL-1 beta by organ cultures of inflamed mucosa from the same patients. Secretion of TNF-alpha by PBMCs was inhibited by about 50% at a PTX concentration of 25 micrograms/ml (IC50). PTX was equally potent in cultures from controls, patients with Crohn's disease, and those with ulcerative colitis. The concentrations of IL-6 and IL-8 were not significantly modified in PBMCs, but IL-6 increased slightly in organ culture supernatants. CONCLUSIONS: PTX or more potent related compounds may represent a new family of cytokine inhibitors, potentially interesting for treatment of inflammatory bowel disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Oxpentifylline, tumour necrosis factor-alpha and Crohn's disease.

T T MacDonald
Gut 1997 40: 559. [PDF]

This article has been cited by other articles:

• Sands, B. E., Kaplan, G. G. (2007). The Role of TNF{alpha} in Ulcerative Colitis. J Clin Pharmacol 47: 930-941 [Abstract] [Full Text]  
• Di Sabatino, A, Ciccocioppo, R, Cinque, B, Millimaggi, D, Morera, R, Ricevuti, L, Cifone, M G, Corazza, G R (2004). Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53: 70-77 [Abstract] [Full Text]  
• van Deventer, S J H (2002). Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 50: iii47-53 [Abstract] [Full Text]  
• Bauditz, J, Wedel, S, Lochs, H (2002). Thalidomide reduces tumour necrosis factor {alpha} and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200 [Abstract] [Full Text]  
• Ventura, A C S., Bohnke, M (2001). Pentoxifylline influences the autocrine function of organ cultured donor corneas and enhances endothelial cell survival. Br J Ophthalmol 85: 1110-1114 [Abstract] [Full Text]  
• Bodger, K, Bromelow, K, Wyatt, J I, Heatley, R V (2001). Interleukin 10 in Helicobacter pylori associated gastritis: immunohistochemical localisation and in vitro effects on cytokine secretion. J. Clin. Pathol. 54: 285-292 [Abstract] [Full Text]  
• Hartmann, G., Bidlingmaier, C., Siegmund, B., Albrich, S., Schulze, J., Tschoep, K., Eigler, A., Lehr, H. A., Endres, S. (2000). Specific Type IV Phosphodiesterase Inhibitor Rolipram Mitigates Experimental Colitis in Mice. J. Pharmacol. Exp. Ther. 292: 22-30 [Abstract] [Full Text]